Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics.
about
The role of calcium in human aging.Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysisPhysiology and pathophysiology of the calcium-sensing receptor in the kidneyA physiologic-based approach to the evaluation of a patient with hyperphosphatemiaFibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.Renal control of calcium, phosphate, and magnesium homeostasisNegative association between serum parathyroid hormone levels and urinary perchlorate, nitrate, and thiocyanate concentrations in U.S. adults: the National Health and Nutrition Examination Survey 2005-2006Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD.The roles of the skeleton and phosphorus in the CKD mineral bone disorderPhosphate Metabolism in Cardiorenal Metabolic Disease.Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism.Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design.A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation.Low Vitamin D Levels in Children with Fractures: a Comparative Cohort Study.Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.Decreased expression of calcium-sensing receptor and parafibromin in secondary hyperparathyroidism with an abnormal whole PTH/intact PTH ratio.Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD).Parathyroidectomy and heart rate variability in patients with stage 5 CKD.Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease.Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients.Lanthanum carbonate oral powder: satisfaction, preference and adherence in French and Spanish patients with end-stage renal disease.Association of Beta-2 Microglobulin with Inflammation and Dislipidemia in High-Flux Membrane Hemodialysis Patients.Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges.Emerging drugs for secondary hyperparathyroidism.Cinacalcet and Clinical Outcomes in Dialysis.Phosphate Binders and Clinical Outcomes in Patients with Stage 5D Chronic Kidney Disease.Proton pump inhibitor-induced hypomagnesaemia and hypocalcaemia: case review.Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.Tradeoff-in-the-Nephron: A Theory to Explain the Primacy of Phosphate in the Pathogenesis of Secondary Hyperparathyroidism.Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel d-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide).Parathyroidectomy improves cardiovascular outcome in nondiabetic dialysis patients with secondary hyperparathyroidism.Effect of Cinacalcet Combined with Calcitriol on the Clinical Outcome and Bone Metabolism in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism.Interrelated role of Klotho and calcium-sensing receptor in parathyroid hormone synthesis and parathyroid hyperplasia.Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.Racial Variations in the Markers of Mineral Bone Disorders in CKD Patients in South Africa.Calcium Carbonate versus Sevelamer Hydrochloride as Phosphate Binders after Long-Term Disease Progression in 5/6 Nephrectomized Rats
P2860
Q27693833-5D6DCE6D-3A5E-404A-93A4-1FF2276B45C9Q30408489-80E4B4F1-C8A8-4E3B-ADD9-53192D3CED29Q33727776-469D43D4-58C6-40CA-AD58-4B074112C97DQ33894092-751031DA-E429-4AC9-9ED2-104EF0150B98Q33944788-8FD71615-B9FB-46E0-B87C-4B8834E9CCA3Q34362759-1CF74DF6-1CA3-4E03-9866-92A6DDE2E8CDQ34442093-C27BFD37-F8EE-4DD8-BE3A-A80976C8659CQ34713301-A218B875-D03A-4E46-8C66-03994EF6BDFDQ34726849-3B2A2D05-2166-4090-B1AF-B6FE8ED0759EQ35013304-8D2F2CDF-3C5D-469A-83E1-764ABBC4B550Q35546322-B607B193-70E2-4CEA-8865-DC6472F50CD8Q35658726-B93A00A2-1BBA-425C-A9A9-BD7E007A166EQ35824855-436F5E87-3E53-4143-B64E-601E22D9486FQ36381365-38DB8A1D-3948-4FE9-A103-D1B7CEBE06F5Q36638009-ECD8415E-D609-4A6B-B91F-20154F9A847BQ36947319-44F01B67-6430-40FF-BE04-67D923EA0D71Q36982088-D206D1D1-B0A0-4FDD-B849-F2D5F1D214A2Q37035502-D711D792-59DA-4FA5-9BC7-271BCFB4E061Q37065618-7B715427-4A4E-4EFC-AF2E-6A82B011E6DCQ37108009-BF52E7A8-BE06-42C4-8749-53FE80560109Q37123151-01148FCB-9E0A-42E9-8C68-146A89640CDEQ37368351-D3476E0E-637B-4A27-A26A-0829A82046EBQ37470972-6A6F426F-6ACC-4EDA-B2F0-25E142B30F05Q37807991-26FDD6F7-CBD3-417E-8C7E-111CEC21C2E6Q38363615-638D3D9A-1EFD-47ED-B413-7C2F5C0058BAQ38565049-1E0F2B58-8F6A-4428-8FEA-99F0827B16AFQ38567745-EA0317B1-F8C5-411A-83CA-62E06983C2E5Q39080559-6EC6DDB3-D03D-4160-B81E-EE61708D9F5CQ39374348-B89876FE-5446-4D87-B4B2-7DE80E44483BQ42233431-623BF707-D9FF-43B4-9E17-2EC9AF7BFB51Q43743367-3C9F8420-8EDF-41B2-BF6A-E90A3D9CF457Q48417341-AD7D5BF6-6876-4EEB-B919-8FE84D873B9AQ50026683-ADE2A52F-8E35-4F17-AE52-503CAD37EC6CQ52721559-75FFA0F6-133B-4D3B-A425-099486117EA9Q53551519-815FC1E0-8E5E-4957-A412-C1A5DD5B0CEFQ55265825-A89A932B-D49A-47E6-9ED0-D6D53215D693Q59049932-BEE70E2C-5D39-4DB8-BA30-366F1E3FAC0C
P2860
Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Development and progression of ...... ssons from molecular genetics.
@en
type
label
Development and progression of ...... ssons from molecular genetics.
@en
prefLabel
Development and progression of ...... ssons from molecular genetics.
@en
P356
P1433
P1476
Development and progression of ...... ssons from molecular genetics.
@en
P2093
L D Quarles
William G Goodman
P2888
P304
P356
10.1038/SJ.KI.5002287
P407
P577
2007-06-13T00:00:00Z
P5875
P6179
1050998353